文献速递神经重症神经肿瘤

颅内耳念珠菌感染:一例病例报告与范围综述

Intracranial Candida Auris Infection: A Case Report and Scoping Review.
PubMed 文献 · World Neurosurg · 2026-01-02

该研究报道一例耳念珠菌中枢神经系统感染病例,并对2009至2025年间成人病例进行范围综述,共纳入9篇文献11例病例。患者年龄33至71岁,常见发热、头痛、意识改变、局灶性缺损或脑积水;脂质体两性霉素B最常用,棘白菌素单药因中枢穿透差不可靠。8例恢复且后遗症轻微,4例有显著并发症或死亡。

要点

  • 神经外科装置显著增加中枢神经系统耳念珠菌感染风险。
  • 快速诊断和药敏指导治疗至关重要。
  • 靶向全身和中枢两个隔室的方案可能改善结局。

核心结论

  • 神经外科装置显著增加中枢神经系统耳念珠菌感染风险,快速诊断和药敏指导治疗至关重要,靶向全身和中枢隔室的方案可能改善结局,装置管理是关键。

研究设计与样本

  • 病例报告联合范围综述,检索PubMed、Embase、Scopus、Web of Science和Europe PMC从2009年至2025年,最终纳入9篇文献描述11例成人病例。

主要发现

  • 患者年龄33至71岁,常见表现包括发热、头痛、意识改变、局灶性缺损或脑积水。
  • 脑脊液分析通常显示细胞增多、蛋白升高和葡萄糖降低。
  • 脂质体两性霉素B最常用,常联合氟胞嘧啶或棘白菌素;棘白菌素单药因中枢穿透差不可靠。
  • 鞘内棘白菌素联合全身氟胞嘧啶在选定病例中实现快速清除;伏立康唑-米卡芬净组合显示前景。
  • 8例恢复且后遗症轻微,4例有显著并发症或死亡。

临床怎么用

  • 对神经外科装置相关中枢感染应警惕耳念珠菌,尽早进行培养和分子诊断。
  • 根据药敏结果选择脂质体两性霉素B为基础、可联合氟胞嘧啶或棘白菌素的方案,避免棘白菌素单药。
  • 重视装置管理,必要时移除感染装置。

局限性

  • 仅基于病例报告和范围综述,证据级别有限。
  • 样本量小(11例),无法得出标准化治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Candida auris (C. auris) is a multidrug-resistant yeast capable of causing invasive infections in both immunocompromised and immunocompetent hosts. While bloodstream and wound infections are well described, central nervous system (CNS) involvement remains rare and poorly characterized. We present a case of C. auris CNS infection and a scoping review of adult cases to identify trends in diagnosis and treatment. METHODS: We searched PubMed, Embase, Scopus, Web of Science, and Europe PMC for reports from 2009 to 2025 using CNS-specific and C. auris-specific terms. After deduplication and dual screening, 9 publications describing 11 cases met all criteria. Data on presentation, diagnostics, therapy, surgical intervention, and outcomes were extracted. RESULTS: Patients (aged 33-71 years) commonly presented with fever, headache, altered mental status, focal deficits, or hydrocephalus. Diagnosis relied on culture, molecular methods, or high clinical suspicion. Cerebrospinal fluid analyses typically demonstrated pleocytosis, elevated protein, and hypoglycorrhachia. Liposomal amphotericin B therapy was most frequently employed, often with flucytosine or echinocandins. Echinocandin monotherapy proved unreliable due to poor CNS penetration. Intrathecal echinocandins with systemic flucytosine achieved rapid clearance in selected cases. Voriconazole-micafungin combinations showed promise. Eight patients recovered with minimal sequelae; 4 had significant morbidity or mortality. CONCLUSIONS: Key themes include 1) neurosurgical devices markedly increase CNS C. auris risk, 2) rapid diagnostics and susceptibility-guided therapy are imperative, 3) regimens targeting both systemic and CNS compartments may improve outcomes, and 4) device management is critical. Standardized protocols, multicenter registries, and pharmacokinetic studies are needed to guide treatment of this emerging, life-threatening infection.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Jelkin GL, Heineman AL, Beckett HT, et al. Intracranial Candida Auris Infection: A Case Report and Scoping Review. World Neurosurg. 2026. PMID: 41485597. doi:10.1016/j.wneu.2025.124775

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。